Pathological Appearance of Focal Liver Reactions after Radiotherapy for Hepatocellular Carcinoma

Masahiro Okada, Masayuki Nakano(Nihon University), Hiromi Nihonmatsu(Yokohama City University Medical Center), Tomoko Hyodo(Kindai University), Takahisa Eriguchi(Keio University), Kengo Tomita(Shimizu (Japan)), Atsuya Takeda(Gunma Chuo Hospital), Kenichiro Tago(Nihon University), Kazushi Numata(Yokohama City University Medical Center)
Diagnostics
April 25, 2022
10.3390/diagnostics12051072
Cited by 3

Related Papers

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
|The Lancet|2023|514
Imaging Study of Early Hepatocellular Carcinoma: Usefulness of Gadoxetic Acid–enhanced MR Imaging
|Radiology|2011|354
cHCC‐CCA
|Hepatology|2018|333
Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH‐HCC Guidelines)
|Hepatology Research|2023|281